Drug therapies pharmacogenomics-based

This situation of escalating costs from improved survival is not new our society has traditionally spent more for incremental (sometimes minor) improvements in care. From an economic perspective, the question becomes how much more and for how long. Every additional dollar spent on health care is another dollar from the Gross Domestic Product (GDP) that cannot be used for other purposes. This opportunity cost of technological improvement will be one of the primary economic and social issues that must be addressed. Pharmacogenomics-based drug therapies will likely provide a test case. Will these new and expensive therapies be rationed if so, on what basis Will our society continue to value improvements in health care above other goods and services such as education, the environment, and Social Security ... 

---